| Drug Name: | Methyldopa (555-30-6) |
|---|---|
| PubChem ID: | 38853 |
| SMILES: | C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N |
| InchiKey: | CJCSPKMFHVPWAR-JTQLQIEISA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Sympatholytics |
| Molecular Weight (dalton) | : | 211.217 |
| LogP | : | 0.4423 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 103.78 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Levodopa (59-92-7) | Blood Pressure Decreased | Additive | The increased hypotension may simply be due to the additive effects of the two drugs | Interaction between levodopa and methyldopa |
| Levodopa (59-92-7) | Dyskinesia | Synergistic | Methyldopa inhibits the breakdown of levodopa outside the brain (by dopa decarboxylase) so that more is available to exert its therapeutic effects. | Methyldopa or methyldopahydrazine as levodopa synergists |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category